What is the price target for LRMR stock?
17 analysts have analysed LRMR and the average price target is 16.97 USD. This implies a price increase of 233.38% is expected in the next year compared to the current price of 5.09.
NASDAQ:LRMR • US5171251003
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for LARIMAR THERAPEUTICS INC (LRMR).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-20 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-03-03 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-02-25 | Wedbush | Reiterate | Outperform -> Outperform |
| 2026-02-25 | Citigroup | Maintains | Buy -> Buy |
| 2025-10-02 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-30 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-09-30 | Baird | Maintains | Outperform -> Outperform |
| 2025-08-19 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-08-15 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-06-25 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-06-24 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-06-24 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-03-25 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-03-25 | Baird | Maintains | Outperform -> Outperform |
| 2025-03-25 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-29 | Truist Securities | Initiate | Buy |
| 2025-01-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-16 | Oppenheimer | Initiate | Outperform |
| 2024-10-03 | Wedbush | Initiate | Outperform |
| 2024-10-02 | HC Wainwright & Co. | Initiate | Buy |
| 2024-09-12 | Jones Trading | Initiate | Buy |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A 1,816.14% | N/A 269.02% | N/A 33.54% | N/A 76.37% | N/A 2.57% | N/A -23.80% | N/A 5.91% | ||||||||||||
| EBITDA YoY % growth | -73.743M | -58.013M 21.33% | -52.811M 8.97% | -60.861M -15.24% | -39.838M 34.54% | -42.649M -7.06% | -50.139M -17.56% | -36.208M 27.78% | -41.447M -14.47% | -90.572M -118.52% | -172.147M -90.07% | N/A 10.35% | N/A 2.94% | N/A 58.69% | N/A 256.42% | N/A 244.55% | N/A 58.36% | N/A 18.58% | N/A | |
| EBIT YoY % growth | -73.813M | -58.225M 21.12% | -52.999M 8.98% | -61.122M -15.33% | -40.101M 34.39% | -42.804M -6.74% | -50.465M -17.90% | -36.526M 27.62% | -41.758M -14.32% | -90.89M -117.66% | -172.497M -89.79% | N/A -4.47% | N/A 5.24% | N/A 81.16% | N/A 656.80% | N/A 179.66% | N/A -22.87% | N/A 18.74% | N/A -28.91% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | -33.24 | -25.44 23.47% | -22.92 9.91% | -23.40 -2.09% | -13.20 43.59% | -3.94 70.15% | -2.97 24.62% | -1.54 48.15% | -0.85 44.81% | -1.30 -52.94% | -2.21 -70.00% | N/A 15.45% | N/A 16.13% | N/A 12.78% | N/A -32.09% | N/A 29.94% | N/A 33.87% | N/A 47.56% | N/A 53.49% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.57 -23.07% | -0.49 -19.63% | -0.47 23.02% | -0.48 34.12% | -0.57 -0.54% | -0.12 74.98% | -0.53 -12.15% | -0.48 -0.53% | -0.49 13.62% | -0.43 -249.87% | -0.32 39.19% | -0.30 38.82% |
| Revenue Q2Q % growth | 82.224M | 12.478M | 16.993M | N/A | N/A | N/A | N/A | |||||
| EBITDA Q2Q % growth | -40.069M -28.84% | -43.469M -57.40% | -46.453M 5.65% | -51.287M 19.45% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -55.944M -79.38% | -49.937M -79.68% | -48.934M 1.14% | -50.973M 20.38% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
17 analysts have analysed LRMR and the average price target is 16.97 USD. This implies a price increase of 233.38% is expected in the next year compared to the current price of 5.09.
LARIMAR THERAPEUTICS INC (LRMR) will report earnings on 2026-04-28, after the market close.
The consensus EPS estimate for the next earnings of LARIMAR THERAPEUTICS INC (LRMR) is -0.57 USD and the consensus revenue estimate is 0 USD.
The number of analysts covering LARIMAR THERAPEUTICS INC (LRMR) is 17.